Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report)’s share price rose 0% during trading on Tuesday. The company traded as high as $10.99 and last traded at $10.9910. Approximately 100 shares were traded during mid-day trading, a decline of 98% from the average session volume of 5,100 shares. The stock had previously closed at $10.99.
Drugs Made in America Acquisition Price Performance
The firm has a 50 day moving average price of $10.86 and a two-hundred day moving average price of $10.75.
About Drugs Made in America Acquisition
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
Further Reading
- Five stocks we like better than Drugs Made in America Acquisition
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
